增加EGFR/HER2通路激活有助于Tpl2小鼠皮肤瘤发生
Laura R Purkey1, Stefania Mehedincu1, Charles Irvine1
1Department of Biology, American University, Washington, DC 20016, USA.
Cancers
|October 29, 2025
概括
在小鼠中,瘤进展部位2 (Tpl2) 的丧失加速了皮肤癌. 用Gefitinib或Lapatinib准ErbB信号减少了瘤的发展,这表明皮肤状细胞癌 (cSCC) 的潜在治疗方法.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
- 癌症信号通路 癌症信号通路
背景情况:
- 线素激活蛋白激酶 (MAPK) 途径在皮肤状细胞癌 (cSCC) 中经常受到失调.
- 瘤进展部位2 (Tpl2) 是一个调节增殖,存活和炎症的MAPK激酶.
- 失去TPL2功能激活了补偿信号,增加了乳头瘤和cSCC的发展.
研究的目的:
- 为了调查是否失调的ErbB信号传递有助于增加Tpl2缺乏小鼠的瘤负担.
- 评估针对TPL2-关联cSCC中的ErbB信号的治疗潜力.
主要方法:
- 野生型 (Tpl2+/+) 和Tpl2-/-小鼠接受了为期48周的化学致癌方案.
- 在他们的饮食中,小鼠接受了Gefitinib (EGFR抑制剂) 或Lapatinib (HER2抑制剂).
- 对ErbB家族成员的基因和蛋白质表达以及相关的微RNA (miRs) 在角质细胞和乳头瘤中进行了分析.
主要成果:
- Tpl2 除增加了EGFR,HER2和HER3基因表达,并提高了乳头瘤中的p-EGFR,EGFR和HER2蛋白水平.
- Tpl2损失与HER2/3相关的miRs205和21在角质细胞中增加相关.
- Tpl2-/-小鼠的乳头瘤和cSCC显著增加;格菲提尼布和拉帕提尼布治疗减少了瘤负担并恢复了cSCC数量.
结论:
- 由Tpl2损失驱动的失调的ErbB信号,有助于加强cSCC的发展.
- 针对ErbB信号通路 (EGFR,HER2) 是与MAPK通路变化相关的cSCC的有前途的治疗策略.
- 抑制EGFR和HER2有效地减少了Tpl2缺乏的小鼠模型中的瘤进展.
相关概念视频
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)

